{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:48:17Z","timestamp":1786373297692,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.2215\/cjn.10661013","type":"journal-article","created":{"date-parts":[[2014,6,27]],"date-time":"2014-06-27T00:03:58Z","timestamp":1403827438000},"page":"1620-1626","source":"Crossref","is-referenced-by-count":66,"title":["A Randomized Multicenter Trial of Paricalcitol versus Calcitriol for Secondary Hyperparathyroidism in Stages 3\u20134 CKD"],"prefix":"10.2215","volume":"9","author":[{"given":"Daniel W.","family":"Coyne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cybele","family":"Ghossein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M.","family":"Sprague","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20230601","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease.","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney Int"},{"key":"R2-18-20230601","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1016\/j.clinthera.2004.12.011","article-title":"Secondary hyperparathyroidism: Review of the disease and its treatment.","volume":"26","author":"de Francisco","year":"2004","journal-title":"Clin Ther"},{"key":"R3-18-20230601","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1053\/ajkd.2001.28110","article-title":"Suppression of parathyroid hormone secretion in hemodialysis patients: Comparison of paricalcitol with calcitriol.","volume":"38","author":"Sprague","year":"2001","journal-title":"Am J Kidney Dis"},{"key":"R4-18-20230601","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1046\/j.1523-1755.2003.00878.x","article-title":"Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism.","volume":"63","author":"Sprague","year":"2003","journal-title":"Kidney Int"},{"key":"R5-18-20230601","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000109398","article-title":"Oral paricalcitol for the treatment of secondary hyperparathyroidism in patients on hemodialysis or peritoneal dialysis.","volume":"28","author":"Ross","year":"2008","journal-title":"Am J Nephrol"},{"key":"R8-18-20230601","doi-asserted-by":"crossref","first-page":"840","DOI":"10.7326\/0003-4819-147-12-200712180-00004","article-title":"Meta-analysis: Vitamin D compounds in chronic kidney disease.","volume":"147","author":"Palmer","year":"2007","journal-title":"Ann Intern Med"},{"key":"R9-18-20230601","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2215\/CJN.03850609","article-title":"Control of secondary hyperparathyroidism by vitamin D receptor agonists in chronic kidney disease.","volume":"5","author":"Sprague","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"R10-18-20230601","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1067\/mlc.2002.122819","article-title":"Differential effects of 19-nor-1,25-dihydroxyvitamin D(2) and 1,25-dihydroxyvitamin D(3) on intestinal calcium and phosphate transport.","volume":"139","author":"Brown","year":"2002","journal-title":"J Lab Clin Med"},{"key":"R11-18-20230601","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1681\/ASN.V1271468","article-title":"Relative potencies of 1,25-(OH)(2)D(3) and 19-Nor-1,25-(OH)(2)D(2) on inducing differentiation and markers of bone formation in MG-63 cells.","volume":"12","author":"Finch","year":"2001","journal-title":"J Am Soc Nephrol"},{"key":"R12-18-20230601","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1053\/ajkd.2002.36899","article-title":"Differential effects of acute administration of 19-Nor-1,25-dihydroxy-vitamin D2 and 1,25-dihydroxy-vitamin D3 on serum calcium and phosphorus in hemodialysis patients.","volume":"40","author":"Coyne","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"R13-18-20230601","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1159\/000266204","article-title":"Differential effects of paricalcitol and calcitriol on intestinal calcium absorption in hemodialysis patients.","volume":"31","author":"Lund","year":"2010","journal-title":"Am J Nephrol"},{"key":"R14-18-20230601","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1053\/j.ajkd.2005.10.007","article-title":"Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD.","volume":"47","author":"Coyne","year":"2006","journal-title":"Am J Kidney Dis"},{"key":"R15-18-20230601","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1210\/jcem-67-5-929","article-title":"Low dose calcitriol versus placebo in patients with predialysis chronic renal failure.","volume":"67","author":"Nordal","year":"1988","journal-title":"J Clin Endocrinol Metab"},{"key":"R16-18-20230601","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/ki.1989.36","article-title":"1,25(OH)2D3 administration in moderate renal failure: A prospective double-blind trial.","volume":"35","author":"Baker","year":"1989","journal-title":"Kidney Int"},{"key":"R17-18-20230601","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000098561","article-title":"Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease.","volume":"27","author":"Zisman","year":"2007","journal-title":"Am J Nephrol"},{"key":"R18-18-20230601","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4158\/EP.14.1.10","article-title":"Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: A randomized controlled pilot study.","volume":"14","author":"Chandra","year":"2008","journal-title":"Endocr Pract"},{"key":"R19-18-20230601","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.ajkd.2007.04.010","article-title":"Changes in serum 25-hydroxyvitamin D and plasma intact PTH levels following treatment with ergocalciferol in patients with CKD.","volume":"50","author":"Al-Aly","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"R20-18-20230601","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1053\/j.ajkd.2004.01.012","article-title":"Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4.","volume":"43","author":"Coburn","year":"2004","journal-title":"Am J Kidney Dis"},{"key":"R21-18-20230601","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1136\/bmj.310.6976.358","article-title":"Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure.","volume":"310","author":"Hamdy","year":"1995","journal-title":"BMJ"},{"key":"R22-18-20230601","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1053\/ajkd.1998.v32.pm9808145","article-title":"Therapy of secondary hyperparathyroidism with 19-nor-1alpha,25-dihydroxyvitamin D2.","volume":"32","author":"Martin","year":"1998","journal-title":"Am J Kidney Dis"},{"key":"R23-18-20230601","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1038\/ki.2011.207","article-title":"Short-term vitamin D receptor activation increases serum creatinine due to increased production with no effect on the glomerular filtration rate.","volume":"80","author":"Agarwal","year":"2011","journal-title":"Kidney Int"},{"key":"R24-18-20230601","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1097\/01.ASN.0000133041.27682.A2","article-title":"Mineral metabolism, mortality, and morbidity in maintenance hemodialysis.","volume":"15","author":"Block","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R25-18-20230601","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.ki.5002451","article-title":"Vitamin D levels and early mortality among incident hemodialysis patients.","volume":"72","author":"Wolf","year":"2007","journal-title":"Kidney Int"},{"key":"R26-18-20230601","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1097\/MNH.0b013e328365b3a3","article-title":"What have we learned about chronic kidney disease-mineral bone disorder from the EVOLVE and PRIMO trials?","volume":"22","author":"Moe","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R27-18-20230601","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1681\/ASN.2007111164","article-title":"Association of oral calcitriol with improved survival in nondialyzed CKD.","volume":"19","author":"Shoben","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"R28-18-20230601","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): A randomised controlled trial.","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"R29-18-20230601","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2012.120","article-title":"Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial.","volume":"307","author":"Thadhani","year":"2012","journal-title":"JAMA"},{"key":"R30-18-20230601","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1038\/ki.2013.145","article-title":"No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease.","volume":"84","author":"Mehrotra","year":"2013","journal-title":"Kidney Int"}],"container-title":["Clinical Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/01277230-201409000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T13:44:29Z","timestamp":1786369469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/01277230-201409000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.2215\/cjn.10661013","relation":{},"ISSN":["1555-9041"],"issn-type":[{"value":"1555-9041","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}